France's Sanofi to buy biotech firm Synthorx for $2.5 billion
Share:
PARIS (Reuters) - Sanofi said on Monday it had agreed to buy California-headquartered biotechnology firm Synthorx in a cash deal worth about $2.5 billion (1.95 billion pounds) aimed at beefing up the French drugmaker's pipeline of drugs for cancer and auto-immune disorders.Under the deal, Sanofi has offered to buy all the outstanding shares of Synthorx common stock for $68 per share in cash.The $68 per share acquisition price represents a 172% premium to Synthorx’s closing price on Dec. 6,..